Compugen Ltd. Report: January 2025 Form 6-K on Phase 1 Clinical Trial Announcement

Here's the key information extracted from the financial report (Form 6-K) filed by Compugen Ltd. for January 2025:

1. Company Information:

• Name: Compugen Ltd.
• Address: 26 Harokmim Street, Holon 5885849, Israel.

2. Filing Type:

• This document is a Form 6-K, which is used by foreign private issuers to report on a variety of events.

3. Filing Date:

• The report is dated January 8, 2025.

4. Commission File Number:

• 000-30902.

5. Press Release:

• On January 8, 2025, Compugen Ltd. issued a press release announcing the first patient dosed in a Phase 1 clinical trial evaluating COM503 as a monotherapy and in combination with Zimberelimab for advanced solid tumors.
• The press release is included as Exhibit 99.1 and is incorporated by reference into the report.

6. Registration Statement Reference:

• The information provided in this report is incorporated by reference into the Company’s Registration Statement on Form F-3, File No. 333-270985.

7. Signatory:

• The report is signed by Eran Ben Dor, General Counsel, on behalf of Compugen Ltd.

Insights:

• The announcement regarding the clinical trial suggests that Compugen is actively progressing in its drug development pipeline, which may have implications for its future revenue potential and market position.
• Investors and analysts may want to monitor the outcomes of this clinical trial closely, as successful results could significantly affect the company's valuation and strategic direction.
• By filing this report and integrating the press release into its official filings, Compugen is maintaining transparency with investors and adhering to regulatory requirements, which is crucial for investor confidence.